开普拓（盐酸伊立替康注射液），适应症为本品适用于晚期大肠癌患者的治疗：·与5-氟尿嘧啶和亚叶酸联合治疗既往未接受化疗的晚期大肠癌患者；·作为单一用药，治疗经含5-氟尿嘧啶化疗方案治疗失败的患者。
开普拓的各种联合化疗方案均显示了相当好的缓解率。
Various combinations of CPT-11 have been studied resulting in a very decent response rate.
目的观察开普拓(CPT 11)联合5 -氟尿嘧啶(5 FU)治疗5 FU耐药晚期大肠癌的效果。
Objective to investigate the effects of camptothecin (CPT 11) plus 5 FU in treating patients with 5 FU resistant advanced colorectal cancer.
在晚期胃癌的临床研究中，泰索帝和开普拓（CPT-11）比奥沙利铂、S-1和其他正在进行早期研究的新药显得更有发达前景。
Taxotere and CPT-11 appear to hold more promise in the investigation of patients with AGC than drugs like oxaliplatin, S-1, or many new classes of compounds that are under early investigation.
应用推荐